NUTLEY, N.J.--(BUSINESS WIRE)--Final 48-week results from an international head-to-head trial, presented today at the 11th European AIDS Conference (EACS), Madrid, demonstrated that treatment-naive HIV patients treated with the protease inhibitor Invirase® 500mg tablets (saquinavir mesylate), boosted with ritonavir, achieved similar levels of viral suppression and increases in CD4 cells compared to those treated with Kaletra® (lopinavir/ritonavir), a commonly used protease inhibitor. Furthermore, fewer patients treated with Invirase developed elevated triglyceride levels.
